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As interventional therapy in acute myocardial infarction has 
evolved, it has become apparent that acute infarct-related 
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coronary artery patency after successful thrombolytic inter- 
vention is associated with both imp 
ventricular function and surviva! (1,2). 
1) Trial (3) s~~ges~~d 
type ~~asrni~o~e~ ac 
ective than i~tr~v~~o~s staff 
ret-related artery in the setting 
of acute myocardial infarction. In another 
domized study (4), intravenous rt-PA resulted in infarct- 
related artery patency in approximately 70% of patients and 
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was comparable in efficacy with intracoronary streptoki- 
nase. 
Concomitant use of coronary angioplasty in addition to 
intravenous &PA produces a slightly higher immediate 
patency rate, but does not alTect recovery of left ventricular 
function and may be associated with lower survival rates 
($6). Therefore, improved infarct-related artery patency 
obtained with lytic agents or combinations f 1ytic agents in 
addition to anticoagulant d antiplatelet agents i desirable. 
A report (7) of a small series of patients suggested that the 
infusion rate of rt-PA correlated with rt-PA levels and that 
infusion rates correlated with higher infarct=related 
patency rates. 
The TM investigators (8) demonstmted that increased 
. Mowever, these in- 
first hour dose of intravenous rt-PA was associated with 
improved infarct-related artery patency without an increase 
in bleeding complications or fibrinogen depletion (9). 
To evaluate he hypothesis that a higher, weight-adjusted 
accelerated infusion of rt-PA over 90 min in acute myocar- 
dial infarction would produce a higher patency rate, we 
performed a randomized multicenter trial assessing the inf- 
arct-related artery 90 min patency and bleeding complication 
rate with two doses of tissue plasminogen activator in acute 
myoc ial infarction. 
t ~I~~~~ Three centers ~artici~ted in this study 
had institutional review board approval. The stud 
was conducted from April through July 20, 
Inclusion criteria included tween I8 and 75 
chest n of at least 30 m tion with characteristics 
consistent with coronary ischemia; ST elevation on the 
electrocardiogram (ERi) of at least 0. I mV in at least wo of 
inferior leads (II, III, aVF) or at least wo precordial 
leads (Vt hrough V,) or leads 1 and aVL; and chest pain 
duration of Cg h before time of treatment. Eight hours was 
felt to be a reasonable cutoff for enrollment because the 
nd point was infarct-related artery patency and there 
clearly established time limit for benefit of thrsmbol- 
time the trial was conducted. Patients were 
consent. 
n pregnancy; bleedin 
or history of significant previous gastrointestinal 
bleeding; cerebrovascularaccident within the past 6 months; 
surgery on an internal organ during the previous 14 
uncontrolled hypertension (diastolic blood pressure 
>120 mm Hg); dilated cardiomyopathy; 
valve; left bundle branch block: previous 
graft; oral anticoagulant therapy, prolonge 
nary resuscitation within the previous 2 
or spinal trauma within the past 6 mo 
shock (systolic blood pressure CgO mm Hg requiting vase- 
pressor therapy or balloon pump, or both). 
Prutocol 
with a total dose not to exce 
or reperfusion defined as 
residual stenosis. Howeve 
~r~~~~, patients were token to 
where they received i~t~vc~ous 
tration of nitrates, a calcium channel or beta-adrenergic 
blocker was allowed if clinically indicated. 
rs and study coordi- 
center eviewed c nary angiograms ob- 
90 min for infarct-related artery patency and 
a consensus opmion was reached. Reperfusion was judged to 
be successful if the in t-related artery demonstrated TIM% 
grade 2 or 3 flow: T grade 0 or I flow represented no
s. Patients whose coro- 
were excluded from the 
patency analysis. Seven patients were excluded at the 60 min 
arteriogram (five who received 2 mg/kg at-PA and t WhO 
received 1.25 mg/kg), and seven were excluded at the min 
arteriogram (three who received 2 mg/kg and four who 
bleeding was describ 
tra~s~~s~o~ re~lacemeat. Life- 
considered to be i~tracraajal or 
chosen to detect a difference in r sion success at the 
to treatment, gender an ret-related artery) in the two 
groups were compared. values for continuous varis 
bles were compared wi e t test, and frequencies for 
categoric variables were compared be 
&i-square test. The primary outcome 
Subgroup analyses based on time from onset of pain lo 
d age versus patency were conducted with use 
uare test for trend, as a prop~iate. ~o~fideace 
intervals for patency rates were calculated by using the 
normal approximation to the binomial, with continuity cor- 
53.5 50.9 
9.9 11.7 
34-72 23-74 
W 
82.7 84.6 
14.6 15.8 
Rimge 52-123 46-127 
uf pirin 10 
3.8 3.6 
I.5 1.4 
tlimge L.3-7.9 I.S-7.9 
Chtkl 
ilk 78 (85.7%) 76 (90.5%) 
~ilf~~r~l~~~l~le~ urtcry 
LCI( 15 (16.4%) 11 (13.1%) 
LAD Jli (41.8%) 30 (35.7%) 
RCA 38 (41.8%) 43 (51.2%) 
*There was no significant difference in any of the variables between the 
two groups. LAD = left a ior descending coronary artery; &Cx = Reft 
circumflex coronery iatery; A = right coronnry artery. 
rection. ortality rates were co 
exact test. 
infarct-related artery 
time from onset of 
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106 
-I PdMI 80 
infarction. 
rison of infarcbr&ted nrtery @W 
1.25 (aold bars) or 2 (hatched ban) m 
en activator during acute 
compared with 70% 61 of 87,95% confidence interval 
78%) in the group that received 1. 
ffect of interventions on imf~~ta~e~ 
(Table 2). The end point of this study 
artery patency before mechanical interventions after 90 min 
of n-PA infusion. Coronary angioplasty or other interven- 
tions including bypass surgery were allowed after 90 min. 
Although it was not an end point of the study, the investi- 
gators considered it to be important to evaluate whether 
different doses of rt-PA had a positive or negative elect on 
subsequent interventions. The percent of patients treated 
with emergency coronary aqioplasty ia the groups receiving 
1.23 or 2.0 mg/kg was equal. Patency of the infarct-related 
cncy anpioplasty was 88% and 89% in the 
25 and 2 mg/kg, respectively. In patients 
with a residual closed infarct-related artery after umsuccess- 
ful recannlizntion by MA, coronary angioplasty was at- 
tempted ira 17 (65%) of the patients receiving 1.25 mg/kg and 
was successful in I I (65%) of these. A 
formed in nine patients with a residual c 
artery in the group receiving 2 mg/kg, and was successful in 
six (67%). At discharge from the catheterization laboratory, 
there was a trend toward improved infarct-related artery 
patency in patients receiving 2 m&kg compared with those 
receiving 1.25 mg/kg ( % versus 83%. respectively), al- 
though this difference not achieve statistical si~~ific~~ce 
(p = 0.08). 
(recurrent chest pain, further 
increase or closed i~~rct-re~~t~ 
of the study, it was maait 
the group receiving 1.25 
4.8% in the group receiving 
additional incremen 
19% in those receivi 
e acute mortality rate in 
as 7.1% compared with 
g+ There was, however, an 
insignificant. although the sample size was not suiIicient to 
detect small changes in mortality. 
In patients with a patent infarct-related coronary artery, 
the acute mortality rate was 4.9% and 2.9%, respectively, in 
the groups receiving 1.25 and 2 mg/kg. At 6 months, among 
patients with an in~ti~~~~~ patent infarct-related artery, the 
mortality rate was 9.8% in those receivi I .25 
compared with 2.9% in those receiving 2.0 m (p = 
No death could be directly attributed ts ait 
there w ence tar cerebral hemorrhage in two patients 
in the h e group; neither of these two patients died as 
a result of the hemorrhage. 
Bleeding cQ~~licatioms (cable 4). A relatively small per- 
cent of patients had significant bleeding, with the majority of 
and at Q, 
Follow-up Study 
I .25 m$kg 2.0 my/kg 
Dose DOSC 
No. Px) No. (Go) p Value 
Inihal admibbion 7191 (7.9) 4184 (4.8) 0.54 @lSJ 
6 month follow-up 10191 (II) 4184 (4 I?t 0.19 (NSI 
Morlnlity in patients with 
palclll II</\ at end 
of iKMIC 
inlcrvenlion 
hiilial artmission 316 I (4.‘)) 2168 (2.0) 0.67 (NSI 
6 month follow-up 6/6 I (9.8) 2168 (2.9) O.IS @JSl 
Abbreviations as in Table 2. 
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Table 4. Bleeding Complications in 175 Patients 
Venipuncture site bleeding 
Gastrointestinal bleeding 
Hematuria 
Catheterization site Lematoma 
Intracranial bleeding 
Retropritoneal bleeding 
Death from bleeding 
All 
Reported 
Bleeding 
73 (42%) 
10 (6%) 
14 (8%) 
2 (1%) 
2 (1%) 
2 (I%,) 
0 (a%) 
Significant Bleeding* 
2.0 @kg I .tS mg/kg 
Dose Dose 
I (I%) 2 (2%) 
0 (0%) I (1%) 
I (1%) 0 (0%) 
0 (0%) I (1%) 
2 (2%) 0 (0%) 
I(I%) I (1%) 
0 (0%) 0 (0%) 
salami]), Therr: is a linear relation between dose over the 
initial 90 min and 90 min infarct-rclatcd artery patt~~y rate, 
with a correlation coefIkknt of 0!?4. 
Th 
severe fibrinogen depletion with higher doses of II-PA, 
radation products after &PA and a 
rt-PA level itself. Top01 et al. (I0 
ted that fibrinogen depletion is dose-dependent wit t 
&PA and that &PA levels were inversely correlated t ” 
fibrinogen depletion, consistent with the reported finding: .l~ 
our study. If fibrinogen depletion alone was responsible, one 
would expect that similar results would be achieved with 
high doses of other activators. After administration of I.5 
million units of streptokinase, Collen et al. (I I) reported that 
fibrin degradation product levels were higher and fibrinogen 
was lower than at?er rt-PA administration; however, repcr- 
fusion was more likely to occur after rt-PA administration. lt 
would, therefore, appear that fibrinogen deplction and fibrin 
degradation products were not complctcly respons~blc for 
improved infarct-related arterial patency. Similar results 
the TIMI investigators (12). These 
ed patency rate is a 
ure risk, Gold et al. (13) in 
ested that coronary reocclusion was 
level, activated partial thromboplas- 
r, they reported de- 
ion of rt-PA, particu- 
larly in patients with >80% residual coronary artery 
stenosis. However, Verstraete et al. (14) believed that there 
was no difference in the reocelusion hen r&PA was not 
continued after the first hour. The investigators (IS) 
ested that when r&PA and uroGnnse were infused 
tanesusly, the reocclusion rate was less but the initial 
cy We was the same. Fibrin degradation products and 
n depletion were much higher with the combination 
of rt-PA and urokinase; however, bleeding complications 
were no greater than with r&PA alone. The TAM1 report (15) 
WpOfiS the relation of decreased reclosure to either fibrin- 
infusion in the current 
in Myocardi:~l InF 
Infarction (~1~~~ 
Myocardial Infarct 
platelets in addition to its ctfect on dissolution of A 
stands. circulating fibrino~ 
~st~aterventio~ rcclosure. 
patients with residual total occlusion was associated with 
less abrupt reclosure when patients were tre 
combination of rt-PA and urokinase before 
Treatment with rt-PA alone fa~lQwc 
was associated with a higher mortality rate than 
with &PA and urokinase (15). In our study, it appears that 
the risk of acute reclosure was no different when high dose 
rt-PA was utilized. However, the incidence of recurrent 
ischemic events after initial intervention tended IO be less in 
patients treated with high dose rt-PA. It has been reported 
(18) that ~~t~~ve~o~s rt-PA resulted in i&ret-related artery 
patency in ~~ppro~imately 75% of patients and that the 
addition of coronary angioplasty im this patency rate 
%. In our study, the addition nary angioplasty 
ved patency rates from 70% to 83% in the group that 
received 1.25 kg and from 84% to 91% in the group th 
received 2 m r&PA. Not all patients in our study wi 
residual infarct-related artery occlusion were subjected to 
rescue coronary angioplasty. This difference in protocol may 
-- 
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